Subgroup | Strategy | Total costs (microcosting) | Total costs (tariff) | Total QALYs | Average time to cure (days) | Inappropriate treatments | Mean number of visits/person | Return clinic visits* | Infected partners | PID cases in women |
All | SC | £113 058 655 | £172 364 138 | 146 532 | 4.3 | 258 395 | 1.3 | 328 726 | 1876 | 176 |
POC A | £118 704 963 | £151 956 910 | 146 656 | 2.3 | 109 135 | 1.1 | 143 205 | 1414 | 119 | |
POC B | £124 842 003 | £152 288 107 | 146 626 | 2.1 | 200 865 | 1.2 | 146 216 | 1451 | 64 | |
POC C | £125 313 136 | £145 912 757 | 146 867 | 1.1 | 23 260 | 1.1 | 88 259 | 1068 | 64 | |
Women | SC | £65 122 097 | £99 714 696 | 89 533 | 4.4 | 176 604 | 1.3 | 149 216 | 764 | 176 |
POC A | £66 938 018 | £88 960 028 | 89 584 | 2.4 | 76 322 | 1.1 | 51 446 | 524 | 119 | |
POC B | £69 853 645 | £89 101 615 | 89 554 | 2.2 | 128 806 | 1.1 | 52 733 | 535 | 64 | |
POC C | £69 285 504 | £85 008 982 | 89 718 | 1.1 | 1607 | 1.0 | 15 528 | 260 | 64 | |
MSW | SC | £29 572 989 | £46 813 874 | 39 342 | 4.3 | 54 860 | 1.4 | 93 507 | 459 | – |
POC A | £29 995 704 | £40 111 202 | 39 389 | 2.1 | 20 957 | 1.1 | 32 574 | 343 | – | |
POC B | £31 717 478 | £40 614 444 | 39 380 | 2.0 | 54 863 | 1.1 | 37 149 | 360 | – | |
POC C | £31 373 674 | £38 724 875 | 39 443 | 1.2 | 13 218 | 1.1 | 19 971 | 285 | – | |
MSM | SC | £18 363 569 | £25 835 568 | 17 658 | 4.1 | 26 931 | 1.7 | 86 002 | 653 | – |
POC A | £21 771 241 | £22 885 680 | 17 684 | 2.3 | 11 855 | 1.5 | 59 185 | 546 | – | |
POC B | £23 270 880 | £22 572 047 | 17 692 | 1.5 | 17 196 | 1.5 | 56 334 | 556 | – | |
POC C | £24 653 958 | £22 178 900 | 17 706 | 1.2 | 8436 | 1.5 | 52 760 | 524 | – |
*Return clinic visit for results and treatment, a test of cure (routine for NG) or because they remain symptomatic.
GUM, genitourinary medicine; MSM, men-who-have-sex-with-men; MSW, men-who-have-sex-with-women; PID, pelvic inflammatory disease; POC, point-of-care; QALY, quality-adjusted life year; SC, standard care.